Artiva Biotherapeutics (ARTV) Assets Average (2024 - 2026)

Artiva Biotherapeutics (ARTV) has 3 years of Assets Average data on file, last reported at $118.4 million in Q1 2026.

• On a quarterly basis, Assets Average fell 40.9% year-over-year to $118.4 million in Q1 2026; TTM through Mar 2026 was $118.4 million, a 40.9% decrease from a year earlier, with the FY2025 full-year figure at $170.3 million, up 8.21% from the prior year.
• Assets Average for Q1 2026 stood at $118.4 million, down from $139.9 million in the prior quarter.
• Over the last five years, Assets Average for ARTV reached as high as $217.6 million in Q4 2024 and fell as low as $118.4 million in Q1 2026.
• Historically, Assets Average has averaged $166.7 million across 3 years, with a median of $159.1 million in 2025.
• Across the five-year window, Assets Average increased 5.55% in 2025 and sank 40.9% in 2026, its largest moves.
• Year by year, Assets Average stood at $217.6 million in 2024, then slumped by 35.7% to $139.9 million in 2025, then slipped by 15.33% to $118.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $118.4 million in Q1 2026, $139.9 million in Q4 2025, and $159.1 million in Q3 2025.